A growth hormone-releasing hormone antagonist stopped endometrial cancer cells from invading and migrating by suppressing Twist and N-cadherin through the GHRH receptor.
Dose-dependent inhibitionGHRH antagonist suppressed endometrial cancer cell invasion and migration at increasing doses by downregulating two key invasion proteins
What the researchers found
A growth hormone-releasing hormone (GHRH) antagonist inhibited the invasion and migration of endometrial cancer cells in a dose-dependent manner. The mechanism involved suppression of Twist and N-cadherin — two proteins critical for cancer cell motility and the epithelial-to-mesenchymal transition. When the GHRH receptor was knocked down using siRNA, the antagonist's suppressive effects were abolished, confirming the action is mediated specifically through the GHRH receptor. Similarly, independently silencing Twist or N-cadherin each suppressed cell motility, validating these as key downstream targets.
Why it matters
Over 25% of endometrial cancer patients present with invasive disease and metastases. This study identifies a new mechanism by which GHRH antagonists — peptide-based compounds — could combat cancer spread by targeting the molecular machinery of cell invasion, potentially opening a new therapeutic approach for endometrial cancer.
The numbers in context
Dose-dependent inhibition of cell motility · Twist and N-cadherin suppressed · GHRH receptor siRNA abolished effect · >25% of endometrial cancer patients have invasive disease
How the study worked
In vitro laboratory study using human endometrial cancer cell lines. GHRH receptor expression was confirmed by Western blotting and immunohistochemistry. Cancer cell invasion and migration were measured using motility assays after treatment with GHRH antagonist at varying doses. Gene silencing with siRNA was used to knock down the GHRH receptor, Twist, and N-cadherin individually to confirm the signaling pathway.
Who was studied
Human endometrial cancer cell lines (in vitro laboratory study)
What this study cannot tell us
This is an in vitro cell line study, so the findings may not translate directly to human tumors in vivo. No animal models or clinical data were presented. The specific GHRH antagonist used and its dosing are described in relative terms (dose-dependent) without absolute concentrations mentioned in the abstract. The study did not assess effects on normal endometrial cells.
How to read the evidence
This is a preclinical in vitro study using cancer cell lines. While it provides mechanistic insight and identifies a clear signaling pathway, it lacks animal model validation or any clinical data. The findings are hypothesis-generating rather than clinically actionable.
When this study was published
Published in 2017, this study contributed to the growing field of GHRH antagonist cancer research. The pathway it identified (Twist/N-cadherin) remains relevant to ongoing cancer invasion research.
The bigger picture
GHRH antagonists were originally developed to suppress growth hormone secretion, but research has increasingly shown they have direct anti-cancer effects. This study extends that work to endometrial cancer and identifies a specific molecular pathway — Twist/N-cadherin-mediated invasion — adding to the growing evidence that peptide hormone antagonists could serve as targeted cancer therapies.
Questions still open
- Would GHRH antagonists show similar anti-invasive effects in animal models of endometrial cancer?
- Could GHRH antagonists be combined with standard endometrial cancer treatments to reduce metastasis rates?
- Do other reproductive cancers express GHRH receptors and respond similarly to GHRH antagonists?
Common questions
What is a GHRH antagonist and how does it relate to peptides?
What are Twist and N-cadherin and why do they matter in cancer?
Read the original research
Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
Oncotarget, 8(3), 4410-4421
Citation
Wu, Hsien-Ming; Huang, Hong-Yuan; Schally, Andrew V; Chao, Angel; Chou, Hung-Hsueh; Leung, Peter C K; Wang, Hsin-Shih. (2017). Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.. Oncotarget, 8(3), 4410-4421. https://doi.org/10.18632/oncotarget.13877